# Ana Carrizosa Anderson

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 97 papers | 17,501 citations | 34076 52 h-index | 46771 89 g-index |
| 107 all docs | 107 docs citations | 107 times ranked | 19975 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Presence of <scp>Tim</scp>3<sup>+</sup> and <scp>PD</scp>â€1<sup>+</sup><scp>CD8</scp><sup>+</sup><scp>T</scp> cells identifies microsatellite stable colorectal carcinomas with immune exhaustion and distinct clinicopathological features. Journal of Pathology, 2022, 257, 186-197. | 2.1 | 13 |
| 2 | Tim-3 adapter protein Bat3 acts as an endogenous regulator of tolerogenic dendritic cell function. Science Immunology, 2022, 7, eabm0631. | 5.6 | 22 |
| 3 | Tim-3 mediates T cell trogocytosis to limit antitumor immunity. Journal of Clinical Investigation, 2022, 132, . | 3.9 | 25 |
| 4 | Spatial determinants of CD8+ T cell differentiation in cancer. Trends in Cancer, 2022, 8, 642-654. | 3.8 | 8 |
| 5 | Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. Clinical Cancer Research, 2021, 27, 276-287. | 3.2 | 100 |
| 6 | Male sex chromosomal complement exacerbates the pathogenicity of Th17 cells in a chronic model of central nervous system autoimmunity. Cell Reports, 2021, 34, 108833. | 2.9 | 29 |
| 7 | TIM-3 restrains anti-tumour immunity by regulating inflammasome activation. Nature, 2021, 595, 101-106. | 13.7 | 169 |
| 8 | Introduction to the Special Issue: Immuno-oncology. Seminars in Immunology, 2021, 52, 101483. | 2.7 | 0 |
| 9 | PD-L1+ and XCR1+ dendritic cells are region-specific regulators of gut homeostasis. Nature Communications, 2021, 12, 4907. | 5.8 | 18 |
| 10 | Spatially organized multicellular immune hubs in human colorectal cancer. Cell, 2021, 184, 4734-4752.e20. | 13.5 | 256 |
| 11 | 256â€…The TIGIT/CD226/CD155 axis and the effects of combining PD-1/PD-L1 blockade with TIGIT-targeting antibody therapy in syngeneic murine glioblastoma models. , 2021, 9, A277-A278. | | 0 |
| 12 | 641â€…Spatially organized multicellular immune hubs in MMRd and MMRp colorectal cancer. , 2021, 9, A670-A670. | | 0 |
| 13 | Differential pre-malignant programs and microenvironment chart distinct paths to malignancy in human colorectal polyps. Cell, 2021, 184, 6262-6280.e26. | 13.5 | 125 |
| 14 | TIM3 comes of age as an inhibitory receptor. Nature Reviews Immunology, 2020, 20, 173-185. | 10.6 | 535 |
| 15 | An IL-27-Driven Transcriptional Network Identifies Regulators of IL-10 Expression across T Helper Cell Subsets. Cell Reports, 2020, 33, 108433. | 2.9 | 54 |
| 16 | NRP1 cripples immunological memory. Nature Immunology, 2020, 21, 972-973. | 7.0 | 4 |
| 17 | Endogenous Glucocorticoid Signaling Regulates CD8+ T Cell Differentiation and Development of Dysfunction in the Tumor Microenvironment. Immunity, 2020, 53, 658-671.e6. | 6.6 | 98 |
| 18 | T cell factor 1: A master regulator of the T cell response in disease. Science Immunology, 2020, 5, . | 5.6 | 85 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Tim-3 finds its place in the cancer immunotherapy landscape. , 2020, 8, e000911. | | 237 |
| 20 | Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. , 2020, 8, e000878. | | 63 |
| 21 | IMMU-09. CONCURRENT DEXAMETHASONE LIMITS THE CLINICAL BENEFIT OF IMMUNE CHECKPOINT BLOCKADE IN GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii106-ii106. | 0.6 | 1 |
| 22 | Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity. JCI Insight, 2020, 5, . | 2.3 | 30 |
| 23 | 209â€...Preclinical mechanistic and clinical evaluation of the corticosteroid dexamethasoneâ€™s detrimental effects on immune checkpoint blockade in glioblastoma cancer. , 2020, , . | | 0 |
| 24 | New Clones on the Block. Immunity, 2019, 51, 606-608. | 6.6 | 4 |
| 25 | Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity. Cancer Discovery, 2019, 9, 1754-1773. | 7.7 | 173 |
| 26 | Revolutionizing Cancer Immunology: The Power of Next-Generation Sequencing Technologies. Cancer Immunology Research, 2019, 7, 168-173. | 1.6 | 10 |
| 27 | Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1â^’CD8+ Tumor-Infiltrating T Cells. Immunity, 2019, 50, 181-194.e6. | 6.6 | 424 |
| 28 | Endogenous T Cell Receptor Rearrangement Represses Aggressive Central Nervous System Autoimmunity in a TcR-Transgenic Model on the Non-Obese Diabetic Background. Frontiers in Immunology, 2019, 10, 3115. | 2.2 | 5 |
| 29 | Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma. Clinical Cancer Research, 2018, 24, 2574-2584. | 3.2 | 40 |
| 30 | Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity. Journal of Immunology, 2018, 200, 3000-3007. | 0.4 | 118 |
| 31 | Blockade of Tim-3 binding to phosphatidylserine and CEACAM1 is a shared feature of anti-Tim-3 antibodies that have functional efficacy. OncoImmunology, 2018, 7, e1385690. | 2.1 | 80 |
| 32 | Induction and transcriptional regulation of the co-inhibitory gene module in T cells. Nature, 2018, 558, 454-459. | 13.7 | 336 |
| 33 | Abstract 2727: The discovery and characterization of PTZ-201, a fully-human, high affinity, antagonistic anti-TIGIT monoclonal antibody. , 2018, , . | | 0 |
| 34 | <scp>TIGIT</scp> and <scp>CD</scp>96: new checkpoint receptor targets for cancer immunotherapy. Immunological Reviews, 2017, 276, 112-120. | 2.8 | 351 |
| 35 | Molecular Dissection of CD8 + T-Cell Dysfunction. Trends in Immunology, 2017, 38, 567-576. | 2.9 | 51 |
| 36 | Abstract A10: A distinct gene module for T cell dysfunction uncoupled from T cell activation and controlled by metallothioneins. , 2017, , . | | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity, 2016, 44, 989-1004. | 6.6 | 1,538 |
| 38 | A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells. Cell, 2016, 166, 1500-1511.e9. | 13.5 | 315 |
| 39 | TIM3 Mediates T Cell Exhaustion during Mycobacterium tuberculosis Infection. PLoS Pathogens, 2016, 12, e1005490. | 2.1 | 147 |
| 40 | Abstract B085: Combining transcriptomic profiling and genome engineering to dissect regulation of tumor immunology. , 2016, , . | | 0 |
| 41 | The Non-Obese Diabetic Mouse Strain as a Model to Study CD8+ T Cell Function in Relapsing and Progressive Multiple Sclerosis. Frontiers in Immunology, 2015, 6, 541. | 2.2 | 21 |
| 42 | TIGIT predominantly regulates the immune response via regulatory T cells. Journal of Clinical Investigation, 2015, 125, 4053-4062. | 3.9 | 470 |
| 43 | Consensus nomenclature for CD8<sup>+</sup>T cell phenotypes in cancer. OncoImmunology, 2015, 4, e998538. | 2.1 | 119 |
| 44 | A T cell extrinsic mechanism by which IL-2 dampens Th17 differentiation. Journal of Autoimmunity, 2015, 59, 38-42. | 3.0 | 7 |
| 45 | Combination immunotherapy: Where do we go from here?. , 2015, 3, . | | 3 |
| 46 | An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction. Nature Communications, 2015, 6, 6072. | 5.8 | 169 |
| 47 | CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature, 2015, 517, 386-390. | 13.7 | 525 |
| 48 | Coinhibitory receptors and CD8 T cell exhaustion in chronic infections. Current Opinion in HIV and AIDS, 2014, 9, 439-445. | 1.5 | 64 |
| 49 | Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape. Cancer Immunology Research, 2014, 2, 393-398. | 1.6 | 278 |
| 50 | Galectin-9-CD44 Interaction Enhances Stability and Function of Adaptive Regulatory T Cells. Immunity, 2014, 41, 270-282. | 6.6 | 249 |
| 51 | PD-1 and Tim-3 Regulate the Expansion of Tumor Antigenâ€"Specific CD8+ T Cells Induced by Melanoma Vaccines. Cancer Research, 2014, 74, 1045-1055. | 0.4 | 179 |
| 52 | Comment on â€œTim-3 Directly Enhances CD8 T Cell Responses to Acute <i>Listeria monocytogenes</i> Infectionâ€. Journal of Immunology, 2014, 193, 467-467. | 0.4 | 5 |
| 53 | Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade. Cancer Immunology Research, 2014, 2, 410-422. | 1.6 | 322 |
| 54 | IL-1Î² Promotes Antimicrobial Immunity in Macrophages by Regulating TNFR Signaling and Caspase-3 Activation. Journal of Immunology, 2013, 190, 4196-4204. | 0.4 | 180 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | TIM3<sup>+</sup>FOXP3<sup>+</sup>regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. OncoImmunology, 2013, 2, e23849. | 2.1 | 251 |
| 56 | A Transgenic Model of Central Nervous System Autoimmunity Mediated by CD4+ and CD8+ T and B Cells. Journal of Immunology, 2012, 188, 2084-2092. | 0.4 | 59 |
| 57 | Editorial: Tim-3 puts on the brakes. Journal of Leukocyte Biology, 2012, 91, 183-185. | 1.5 | 6 |
| 58 | Contrasting acute graft-versus-host disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells. Blood, 2012, 120, 682-690. | 0.6 | 47 |
| 59 | Tim-3, a negative regulator of anti-tumor immunity. Current Opinion in Immunology, 2012, 24, 213-216. | 2.4 | 175 |
| 60 | Bat3 promotes T cell responses and autoimmunity by repressing Tim-3â€“mediated cell death and exhaustion. Nature Medicine, 2012, 18, 1394-1400. | 15.2 | 303 |
| 61 | Immune checkpoints in central nervous system autoimmunity. Immunological Reviews, 2012, 248, 122-139. | 2.8 | 90 |
| 62 | Emerging Tim-3 functions in antimicrobial and tumor immunity. Trends in Immunology, 2011, 32, 345-349. | 2.9 | 215 |
| 63 | Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood, 2011, 117, 4501-4510. | 0.6 | 554 |
| 64 | Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. Journal of Experimental Medicine, 2011, 208, 1331-1331. | 4.2 | 12 |
| 65 | Differential IL-21 signaling in APCs leads to disparate Th17 differentiation in diabetes-susceptible NOD and diabetes-resistant NOD.Idd3 mice. Journal of Clinical Investigation, 2011, 121, 4303-4310. | 3.9 | 46 |
| 66 | Abstract SY19-02: Role of the Tim-3 and PD-1 pathways in T cell exhaustion and antitumor immunity. , 2011, , . | | 0 |
| 67 | Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. Journal of Experimental Medicine, 2010, 207, 2187-2194. | 4.2 | 1,652 |
| 68 | Tim-3/Tim-3L Pathway as a Target for Restoring Effector Functions in Exhausted CD8 Lymphocytes in Tumors. Clinical Immunology, 2010, 135, S12. | 1.4 | 0 |
| 69 | Tâ€bet, a Th1 transcription factor regulates the expression of Timâ€3. European Journal of Immunology, 2010, 40, 859-866. | 1.6 | 98 |
| 70 | Tim3 binding to galectin-9 stimulates antimicrobial immunity. Journal of Experimental Medicine, 2010, 207, 2343-2354. | 4.2 | 165 |
| 71 | Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14733-14738. | 3.3 | 697 |
| 72 | TIM-3 and Its Regulatory Role in Immune Responses. Current Topics in Microbiology and Immunology, 2010, 350, 1-15. | 0.7 | 114 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 8706-8711. | 3.3 | 163 |
| 74 | Tim-3/Galectin-9 Pathway: Regulation of Th1 Immunity through Promotion of CD11b+Ly-6G+ Myeloid Cells. Journal of Immunology, 2010, 185, 1383-1392. | 0.4 | 243 |
| 75 | Promoting tolerance to proteolipid protein-induced experimental autoimmune encephalomyelitis through targeting dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 17280-17285. | 3.3 | 66 |
| 76 | New roles for TIM family members in immune regulation. Nature Reviews Immunology, 2008, 8, 577-580. | 10.6 | 121 |
| 77 | Role of Th1 and Th17 cells in organ-specific autoimmunity. Journal of Autoimmunity, 2008, 31, 252-256. | 3.0 | 371 |
| 78 | Cutting Edge: The<i>Idd3</i>Genetic Interval Determines Regulatory T Cell Function through CD11b+CD11câˆ' APC. Journal of Immunology, 2008, 181, 7449-7452. | 0.4 | 18 |
| 79 | TIM-4 Expressed on APCs Induces T Cell Expansion and Survival. Journal of Immunology, 2008, 180, 4706-4713. | 0.4 | 96 |
| 80 | Up-Regulation of Gene Related to Anergy in Lymphocytes Is Associated with Notch-Mediated Human T Cell Suppression. Journal of Immunology, 2007, 178, 6158-6163. | 0.4 | 44 |
| 81 | Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. Journal of Experimental Medicine, 2007, 204, 1691-1702. | 4.2 | 117 |
| 82 | Modulation of CD4 co-receptor limits spontaneous autoimmunity when high-affinity transgenic TCR specific for self-antigen is expressed on a genetically resistant background. International Immunology, 2007, 19, 1235-1248. | 1.8 | 10 |
| 83 | Tim Protein Structures Reveal a Unique Face for Ligand Binding. Immunity, 2007, 26, 273-275. | 6.6 | 10 |
| 84 | Promotion of Tissue Inflammation by the Immune Receptor Tim-3 Expressed on Innate Immune Cells. Science, 2007, 318, 1141-1143. | 6.0 | 623 |
| 85 | CD11b+Ly-6Chi Suppressive Monocytes in Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2007, 179, 5228-5237. | 0.4 | 313 |
| 86 | The dynamics of effector T cells and Foxp3+ regulatory T cells in the promotion and regulation of autoimmune encephalomyelitis. Journal of Neuroimmunology, 2007, 191, 51-60. | 1.1 | 75 |
| 87 | TIM-3 in autoimmunity. Current Opinion in Immunology, 2006, 18, 665-669. | 2.4 | 92 |
| 88 | Up-Regulation of Grail Is Associated with Notch-Mediated Human T-Cell Suppression. Clinical Immunology, 2006, 119, S42. | 1.4 | 0 |
| 89 | The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nature Immunology, 2005, 6, 1245-1252. | 7.0 | 1,697 |
| 90 | The Notch Regulator Numb Links the Notch and TCR Signaling Pathways. Journal of Immunology, 2005, 174, 890-897. | 0.4 | 53 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | IL-10 Plays an Important Role in the Homeostatic Regulation of the Autoreactive Repertoire in Naive Mice. Journal of Immunology, 2004, 173, 828-834. | 0.4 | 47 |
| 92 | Expression of Self-antigen in the Thymus. Journal of Experimental Medicine, 2003, 198, 1627-1629. | 4.2 | 29 |
| 93 | T CELL RESPONSE IN EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS (EAE): Role of Self and Cross-Reactive Antigens in Shaping, Tuning, and Regulating the Autopathogenic T Cell Repertoire. Annual Review of Immunology, 2002, 20, 101-123. | 9.5 | 336 |
| 94 | The origin and regulation of autopathogenic T cells. Journal of Clinical Immunology, 2001, 21, 74-80. | 2.0 | 4 |
| 95 | Autoantigen-Responsive T Cell Clones Demonstrate Unfocused TCR Cross-Reactivity toward Multiple Related Ligands: Implications for Autoimmunity. Cellular Immunology, 2000, 202, 88-96. | 1.4 | 19 |
| 96 | Tuning T cell activation threshold and effector function with cross-reactive peptide ligands. International Immunology, 2000, 12, 205-213. | 1.8 | 40 |
| 97 | High Frequency of Autoreactive Myelin Proteolipid Proteinâ€“Specific T Cells in the Periphery of Naive Mice. Journal of Experimental Medicine, 2000, 191, 761-770. | 4.2 | 254 |